SUMMARY To study the value of low-dose captopril (6.25 and 12.5 mg) and a diuretic combination, the blood pressure and heart rate of 17 patients with moderate-to-severe hypertension were monitored for 6 hours (hospital) or 3 hours (office) after the single low-dose or larger (25, 50, 100 and 150 mg) captopril dosage. All patients had preserved renal functiotn and were taking an oral diuretic (hydrochlorothiazide or furosemide) for at least 4 weeks. The 
normalized the supine blood pressure of 35% of these patients acutely. We suggest that in hypertensive patients already taking a diuretic, a lower starting dose of captopril than the recommended 25 mg three times daily may be desirable.
CAPTOPRIL (SQ 14225), inhibitor of the peptidyl dipeptide hydrolase (kininase II), is a useful adjunct in the medical treatment of moderate-to-severe arterial hypertension'-' and refractory congestive heart failure. 4 There have been reports of a marked hypotensive response4 6.7 or reversible deterioration in renal function6 ' 11-" after acute captopril administration. It may produce new or aggravate preexisting protein- A10 12 uria in 1.2% of patients, usually those with primary renal parenchymal disease or concomitant systemic diseases, within the first 4 months of therapy. Rarely, leukopenia and agranulocytosis 3'-1 or pancytopenial6 have been reported. Captopril-related skin rashes and taste abnormalities occur in up to 10% of the patients, but can be controlled by decreasing the dose or by short-term discontinuation of captopril. 1 l 6. 9, 10. 17, 18 Oral diuretics are most frequently combined with other antihypertensive drugs, including captopril, in the treatment of moderate-to-severe hypertension. The marked acute hypotensive response and reversible worsening of renal function may be minimized by beginning therapy with 6.25 or 12.5 mg instead of 25 mg of captopril. No such data, however, are available.
There have been three reports'9-21 of blood pressure monitoring with the starting dose of 25 or 50 mg with or without concomitant diuretic therapy. The objectives of this study were to monitor the supine and upright arterial blood-pressure and heart rate after 6.25-150 mg of captopril and to determine its efficacy and safety in the long-term control of hypertensive patients receiving a diuretic for at least 4 weeks before and during captopril treatment.
Methods

Patients
Seventeen hypertensive patients (seven men and 10 women) were hospitalized for captopril treatment. Each gave informed, written consent for the study.
Fifteen patients were white, one was black and one was oriental. They were 30-65 years old (mean 44 ± 3 years L ± SEM]). The known duration of hypertension was 6.4 ± 2.0 years. The highest previously documented arterial blood pressures (mean ± SEM) were 213 ± 7/128 ± 3 mm Hg. All patients had at least Keith-Wagner grade II hypertensive retinopathy or had an episode of grade III or IV retinopathy 1 year before entering the study. To determine the etiology of hypertension and the presence of end-organ damage, each patient had a thorough laboratory assessment, including renal arteriography (when indicated), in addition to the clinical evaluation. Five patients had renovascular hypertension and 12 essential hypertension. None of the patients had significant impairment of renal function (serum creatinine > 1.6 mg%), cardiac decompensation or acute myocardial infarction in the previous 6 months or history of malabsorption syndrome or serious allergic systemic disorders.
Procedures
All patients were evaluated clinically at least every 2 weeks and on the day of hospital admission. Hydrochlorothiazide was the diuretic in 12 patients, furosemide in three, dyrenium in one and ticrynafen in one patient (later changed to hydrochlorothiazide). In 10 patients, all other antihypertensive drugs were discontinued for 14 of captopril, although other antihypertensive medications were withheld for 24 hours, and she was subsequently titrated on 12.5, 25 and 50 mg of captopril in the hospital without dizziness. Because of recurrent hospitalizations for chest pains in the interim, she was later discontinued from the study after 12 weeks of captopril therapy.
Another patient, a 32-year-old female, had a maculopapular skin rash without fever approximately 4 weeks after starting captopril. The rash disappeared in 4 days after the captopril dosage was decreased from 50 mg to 25 mg three times daily. The lower dosage provided good control of her arterial hypertension. The remaining 15 patients had no adverse clinical reactions during 17 ± 2 weeks of follow-up.
Discussion
This study was undertaken to determine the value of low-dose captopril (less than 25 mg three times daily) in hospitalized patients with moderate-to-severe hypertension. Because these patients were already taking an oral diuretic, they were possibly at a higher risk of developing profound hypotension or significant orthostatic hypotension with captopril administration. Our data suggested that a small dose (6.25 mg) of captopril acutely was as effective as the recommended 25-mg starting dose in these patients. The magnitude and duration of the antihypertensive effect of 6.25 mg was similar to the 12.5-, 25-and 50-mg captopril dose titration ( figs. 1 and 2, tables 1 and 2 ). This finding is in contrast to a report"9 of apparent lack of prolonged duration of action with 6.25-and 12.5-mg doses of captopril in eight patients with mild-to-moderate hypertension taking diuretics. We titrated our patients on 12.5-mg and larger doses of captopril only if after the 6.25-mg dose supine diastolic blood pressure was greater than 80 mm Hg after 3 hours and greater than 90 mm Hg after 6 hours of monitoring. Koffer et al., 19 however, titrated all eight patients successively on 6.25, 12.5 and 25 mg of captopril; two of the eight patients (25%) developed symptomatic orthostasis. Only one of our 17 patients (6%) experienced transient dizziness with further orthostatic blood pressure change with the first 6.25-mg dose of captopril; subsequent doses of 6.25 mg or larger were tolerated without side effects. This patient had a significant orthostatic drop in her blood pressure while taking large doses of furosemide and four other antihypertensive drugs up until 12 hours before captopril.
Six of our 17 patients (35%) were normotensive while taking 6.25 or 12.5 mg of captopril three times daily during their hospitalization. It may be more prudent to start captopril therapy at a 6.25-mg dosage when given in combination with a diuretic or other antihypertensive medications. This precaution should help to minimize the occurrence of acute hypotension and renal failure,6' 9-1 or further compromise of cardiac23 or cerebral function due to sudden lowering of the blood pressure of salt-depleted patients' 17, 24, 25 or in patients with chronic congestive heart failure.4 These hypotension-related complications can be minimized by having patients in fluid and electrolyte equilibrium, compensated cardiac function and avoiding polypharmacy with other agents that block reflex sympathetic control mechanisms, particularly in the upright posture, or affect the renin-angiotensin system. 26 We expected that further increments in captopril dosage would be necessary on outpatient basis in our patients. Seven of our patients (41%) were normotensive with 25-mg or lower-dose captopril three times daily during 17 + 2 weeks of follow-up (three patients received 6.25 mg, one patient 12.5 mg and three patients 25 mg three times daily and a diuretic). Our patients have seemingly done much better than the 16 patients of Vlassess et al.,20 only one of whom (8%) was normotensive with 25 mg of captopril three times a day and a diuretic in mild-to-moderate hypertension followed for 2 weeks, or the eight patients reported by ney or in the postrenal transplant recipients with renal artery stenosis of the transplanted kidney.38 Recently, one of us (GST) had a patient with severe hypertension and decreased renal blood flow to the only kidney with a prior renal artery bypass graft, who was unresponsive to tripledrug (diuretic, /8 blocker, and vasodilator) therapy. The patient developed marked azotemia (76 mg%) and elevated serum creatinine levels (peaked at 4.0 mg%) after receiving a total of 175 mg captopril (in divided doses) over 56 hours. There was concomitant dramatic lowering of the systemic blood pressure. After the substitution of captopril with a methyldopa, the patient was weaned off i.v. sodium nitroprusside infusion. Serum creatinine returned to the precaptopril levels (1.6 mg%) 48 hours after the discontinuation of captopril. 
